Feature|Articles|November 15, 2024
- Pharmaceutical Executive: November 2024
- Volume 44
- Issue 11
Pharmaceutical Executive: November 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
AI’s Attention Spanalmost 2 years ago
Noam Solomon: Bringing the Human Story to AIalmost 2 years ago
Drilling in on Disease Hallmarks: New Tricks to Solve Age-Old Problemsalmost 2 years ago
ROI and Rare Disease: Retooling the ‘Gene’ Value Machinealmost 2 years ago
The Leap Forward: Practical Gains for Pharma AI Usealmost 2 years ago
Powering Pipelines Forward: Approach Science Differentlyalmost 2 years ago
Navigating the Current Landscape for Pharma Leadersalmost 2 years ago
Passage to Asia: Early Access for Innovative Therapiesalmost 2 years ago
Digital Protection: Q&A with Jeffrey BernsteinAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
3
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
4
FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes
5